Clinical Features and Risk Factors of Oedematous Mycobacterium ulcerans Lesions in an Australian Population: Beware Cellulitis in an Endemic Area

PLoS Neglected Tropical Diseases

Volumn 8, Issue 1, 2014, Pages 50-

  O'Brien, Daniel P ^a,b,c   Friedman, N Deborah ^a   McDonald, Anthony ^a   Callan, Peter ^a   Hughes, Andrew ^a   Athan, Eugene ^a  

^a BARWON HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CEFALEXIN; CEFAZOLIN; CEFTRIAXONE; CLINDAMYCIN; DOXYCYCLINE; FLUCLOXACILLIN; GENTAMICIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; BURULI ULCER; CELLULITIS; CLINICAL FEATURE; EDEMA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; LIMB INJURY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OEDEMATOUS MYCOBACTERIUM ULCERANS LESION; PAIN; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; COHORT ANALYSIS; DIFFERENTIAL DIAGNOSIS; ISOLATION AND PURIFICATION; MIDDLE AGED; MYCOBACTERIUM ULCERANS; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BURULI ULCER; CELLULITIS; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM ULCERANS; RISK FACTORS; VICTORIA; YOUNG ADULT;

EID: 84893748184     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002612     Document Type: Article

References (14)

1. Jenkin GA, Smith M, Fairley M, Johnson PD, (2002) Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust 176: 180-181.
2. Trevillyan JM, Johnson PD, (2013) Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy. Med J Aust 198: 443-444.
3. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, et al. (2004) Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis 10: 1391-1398.
4. Steffen CM, Smith M, McBride WJ, (2010) Mycobacterium ulcerans infection in North Queensland: the 'Daintree ulcer'. ANZ J Surg 80: 732-736.
5. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, et al. (2010) Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 54: 3678-3685.
6. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, et al. (2007) Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51: 4029-4035.
7. Portaels F, Silva MT, Meyers WM, (2009) Buruli ulcer. Clin Dermatol 27: 291-305.
8. Pak J, O'Brien DP, Quek TY, Athan E, (2012) Treatment costs of Mycobacterium ulcerans in the antibiotic era. International Health 4: 123-127.
9. World Health Organisation (2012) Treatment of Mycobacterium ulcerans disease (Buruli ulcer): Guidance for health workers. In: Orgainisation WH, editor. Geneva, Switzerland.
10. Moutschen MP, Scheen AJ, Lefebvre PJ, (1992) Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 18: 187-201.
11. Phanzu DM, Mahema RL, Suykerbuyk P, Imposo DH, Lehman LF, et al. (2011) Mycobacterium ulcerans infection (Buruli ulcer) on the face: a comparative analysis of 13 clinically suspected cases from the Democratic Republic of Congo. Am J Trop Med Hyg 85: 1100-1105.
12. O'Brien DP, Robson M, Friedman ND, Walton A, McDonald A, et al. (2013) Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis 13: 416.
13. Guenin-Mace L (2013) Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. WHO Meeting on Buruli ulcer Control and Research. Geneva.
14. Friedman ND, McDonald A, Robson M, O'Brien DP, (2012) Corticosteroid Use for Paradoxical Reactions during Antibiotic Treatment for Mycobacterium ulcerans. PLoS Negl Trop Dis 6: e1767.